サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1764940

アジア太平洋の生物製剤市場の予測 (2031年まで) - 地域別分析 (製品別、用途別、原料別、製造手法別)

Asia Pacific Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing

出版日
ページ情報
英文 163 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
アジア太平洋の生物製剤市場の予測 (2031年まで) - 地域別分析 (製品別、用途別、原料別、製造手法別)
出版日: 2025年04月14日
発行: The Insight Partners
ページ情報: 英文 163 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋の生物製剤市場は、2023年に1,015億9,050万米ドルと評価され、2031年には4,170億8,290万米ドルに達すると予測され、2023年から2031年までのCAGRは19.3%と推定されます。

新興国市場におけるバイオテクノロジーの進化がアジア太平洋の生物製剤市場を後押し

抗体は、基礎研究から革新的な医療治療アプローチまで、現代のバイオテクノロジーにおける数多くの用途で必要とされています。治療用抗体の開発により、様々な疾患の治療に新たな道が開かれ、この粒子の変換能力が実証されています。抗体はまた、病気の同定に正確で信頼できるアプローチを提供するため、診断学においても極めて重要です。アジア太平洋、中南米、中東・アフリカなどの地域では、政府からの支援の増加、官民パートナーシップの台頭、絶えず変化する疾患プロファイル、資金調達活動の活発化により、バイオテクノロジー産業の業績が広く向上しています。UAE、サウジアラビア、オマーン、マスカット、バーレーン、台湾、マレーシア、インド、中国、シンガポール、日本などの国々は、バイオテクノロジー産業にとって最も有利な市場のひとつです。バイオテクノロジー、遺伝学、細胞生物学の進歩は、標的治療のためのいくつかの潜在的治療薬の同定に貢献しています。バイオテクノロジーは中国にとって戦略的セクターです。メイド・イン・チャイナ2025」構想は、革新的な医薬品を含むハイテク製品の製造を支える研究能力に重点を置いています。この計画では、中国の製薬会社がバイオテクノロジーの技術革新に拍車をかけ、輸出を強化するために目標とする分野を紹介しています。アジア諸国は、ゲノミクス、プロテオミクス、バイオマーカーの進歩を診断・治療用途に利用することに、より重点を置いています。したがって、新興国市場におけるバイオテクノロジー産業の進展は、今後数年間、生物製剤市場にチャンスをもたらすと予想されます。

アジア太平洋の生物製剤市場：概要

アジア太平洋の生物製剤市場は、中国、日本、インド、韓国、オーストラリア、その他アジア太平洋に区分されます。この地域の市場成長の原動力は、遺伝的疾患を抱える患者の多さと、各国政府によるヘルスケア研究開発への投資の増加です。ここ数年、中国では生物製剤の利点に対する認識が著しく高まっています。さらに、細胞株の特性評価や前臨床開発から商業化までの多くのリリースのための広範な検査サービスへの現地でのアクセスが増加し、市場の成長に好影響をもたらしました。最近の動向では、科学者や保健当局は、生物製剤が病気の研究や治療、医薬品や医療機器の開発にいかに効果的に利用できるかを強調する努力をしています。また、先天性障害の開発メカニズムに基づく知識の強化にも努めています。サムスンバイオロジクスは、非小細胞肺がん（NSCLC）、トリプルネガティブ乳がん（TNBC）、その他の固形がん治療用の抗体薬物複合体（ADC）開発のため、中国バイオテック・ジーンクアンタム・ヘルスケアと提携契約を締結しました。

アジア太平洋の生物製剤市場の収益と2031年までの予測（金額）

アジア太平洋の生物製剤市場のセグメンテーション

アジア太平洋の生物製剤市場は、製品、用途、供給源、製造、国に分類されます。

製品別では、アジア太平洋の生物製剤市場は、モノクローナル抗体、ワクチン、組み換えホルモン/タンパク質、細胞・遺伝子治療、その他に区分されます。モノクローナル抗体セグメントは2023年に最大の市場シェアを占めました。

用途別では、アジア太平洋の生物製剤市場は、がん、感染症、自己免疫疾患、その他に分類されます。2023年にはがん分野が最大の市場シェアを占めました。

原料別では、アジア太平洋の生物製剤市場は哺乳類と微生物に二分されます。2023年には哺乳類セグメントがより大きな市場シェアを占めました。

製造手法別では、アジア太平洋の生物製剤市場は外部委託と自社製造に二分されます。2023年の市場シェアは、外部委託セグメントがより大きいです。

国別では、アジア太平洋の生物製剤市場は中国、インド、日本、韓国、オーストラリア、その他アジア太平洋に区分されます。2023年には中国がアジア太平洋の生物製剤市場シェアを独占しました。

AbbVie Inc、Pfizer Inc、Samsung Biologics Co Ltd、ADMA Biologics, Inc、Wuxi Biologics Inc、Catalent Inc、AGC Biologics AS、AstraZeneca Plc、Amgen Inc、Nitto Avecia、Quality Assistance s.a.などが、アジア太平洋の生物製剤市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要洞察
  • 市場の魅力

第3章 分析手法

  • 二次調査
  • 一次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の開発
    • データの三角測量
    • 国レベルのデータ

第4章 アジア太平洋の生物製剤市場：主な市場力学

  • 市場促進要因
    • 慢性疾患の増加
    • 製造業務のアウトソーシング志向
  • 市場抑制要因
    • 生物製剤の高コスト
  • 市場機会
    • 開発途上地域におけるバイオテクノロジーの進化
    • 生物製剤における遺伝子・細胞治療の進歩
  • 今後の動向
    • 企業の戦略的取り組み
  • 促進要因と抑制要因の影響

第5章 生物製剤市場：アジア太平洋市場の分析

  • アジア太平洋の生物製剤市場の収益 (2021～2031年)
  • アジア太平洋の生物製剤市場の予測・分析

第6章 アジア太平洋の生物製剤市場の分析：製品別

  • モノクローナル抗体
  • ワクチン
  • 組換えホルモン/タンパク質
  • 細胞・遺伝子治療
  • その他

第7章 アジア太平洋の生物製剤市場の分析：用途別

  • がん
  • 感染症
  • 自己免疫疾患
  • その他

第8章 アジア太平洋の生物製剤市場の分析：原料別

  • 哺乳類
  • 微生物

第9章 アジア太平洋の生物製剤市場の分析：製造手法別

  • 外部委託（アウトソーシング）
  • 自社製造

第10章 アジア太平洋の生物製剤市場：国別分析

  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋

第11章 業界情勢

  • 市場イニシアティブ
  • パートナーシップと提携
  • その他の動向

第12章 企業プロファイル

  • AbbVie Inc
  • Pfizer Inc
  • Samsung Biologics Co Ltd
  • ADMA Biologics, Inc.
  • WuXi Biologics Inc
  • Catalent Inc
  • AGC Biologics AS
  • AstraZeneca Plc
  • Amgen Inc
  • Nitto Avecia
  • Quality Assistance s.a.

第13章 付録

図表

List Of Tables

  • Table 1. Asia Pacific Biologics Market Segmentation
  • Table 2. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Product
  • Table 4. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
  • Table 5. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Source
  • Table 6. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Manufacturing
  • Table 7. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 9. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 10. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 11. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 12. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 13. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 14. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 15. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 16. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 17. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 18. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 19. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 20. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 21. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 22. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 23. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 24. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 25. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 26. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 27. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 28. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 29. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 30. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 31. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing

List Of Figures

  • Figure 1. Asia Pacific Biologics Market Segmentation - Country
  • Figure 2. Asia Pacific Biologics Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Biologics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Asia Pacific Biologics Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Asia Pacific Biologics Market Share (%) - by Application (2023 and 2031)
  • Figure 12. Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Asia Pacific Biologics Market Share (%) - by Source (2023 and 2031)
  • Figure 17. Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Asia Pacific Biologics Market Share (%) - by Manufacturing (2023 and 2031)
  • Figure 20. Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Asia Pacific Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 28. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
目次
Product Code: BMIRE00031590

The Asia Pacific biologics market was valued at US$ 1,01,590.5 million in 2023 and is expected to reach US$ 4,17,082.9 million by 2031; it is estimated to register a CAGR of 19.3% from 2023 to 2031.

Evolution of Biotechnology in Developing Regions Fuels Asia Pacific Biologics Market

Antibodies are required in numerous applications in modern biotechnology, from fundamental research to innovative medical therapeutic approaches. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in the regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most lucrative markets for the biotechnology industry. Advancements in biotechnology, genetics, and cell biology have contributed to the identification of several potential therapeutics for targeted treatments. Biotechnology is a strategic sector for China. The Made in China 2025 initiative emphasizes on research capabilities supporting the manufacturing of high-tech products, including innovative medicines. The plan introduced Chinese pharmaceutical companies to target areas to spur biotechnology innovation and enhance exports. Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing developments in the biotechnology industry in developing regions are expected to create opportunities for the biologics market in the coming years.

Asia Pacific Biologics Market Overview

The biologics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth in the region is driven by a large pool of patients living with genetic conditions and increasing investments in healthcare R&D by governments of respective countries. Over the past few years, there has been a significant rise in awareness about the benefits of biologics in China. Moreover, there was a rise in local access to a broad range of testing services for cell line characterization and many release from preclinical development to commercialization, creating a positive impact on the growth of the market. In recent years, scientists and health authorities have made efforts to highlight how biologics could be effectively utilized to study and treat diseases and develop pharmaceuticals and medical devices. They are also striving to strengthen their knowledge based on the mechanism of development of congenital disabilities. Samsung Biologics has signed a partnership agreement with China Biotech GeneQuantum Healthcare for the development of antibody-drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumors.

Asia Pacific Biologics Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Biologics Market Segmentation

The Asia Pacific biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Asia Pacific biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Asia Pacific biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Asia Pacific biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Asia Pacific biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Asia Pacific biologics market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Asia Pacific biologics market.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Asia Pacific Biologics Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic Diseases
    • 4.1.2 Preference for Outsourcing Manufacturing Operations
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
  • 4.3 Market Opportunities
    • 4.3.1 Evolution of Biotechnology in Developing Regions
    • 4.3.2 Gene and Cell Therapy Advancements in Biologics
  • 4.4 Future Trends
    • 4.4.1 Strategic Initiatives by Companies
  • 4.5 Impact of Drivers and Restraints:

5. Biologics Market - Asia Pacific Analysis

  • 5.1 Asia Pacific Biologics Market Revenue (US$ Million), 2021-2031
  • 5.2 Asia Pacific Biologics Market Forecast Analysis

6. Asia Pacific Biologics Market Analysis - by Product

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Overview
    • 6.1.2 Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.2 Vaccine
    • 6.2.1 Overview
    • 6.2.2 Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.3 Recombinant Hormones/Proteins
    • 6.3.1 Overview
    • 6.3.2 Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.4 Cell and Gene Therapy
    • 6.4.1 Overview
    • 6.4.2 Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Biologics Market Analysis - by Application

  • 7.1 Cancer
    • 7.1.1 Overview
    • 7.1.2 Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Infectious Diseases
    • 7.2.1 Overview
    • 7.2.2 Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Autoimmune Diseases
    • 7.3.1 Overview
    • 7.3.2 Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Biologics Market Analysis - by Source

  • 8.1 Mammalian
    • 8.1.1 Overview
    • 8.1.2 Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Microbial
    • 8.2.1 Overview
    • 8.2.2 Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Biologics Market Analysis - by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Overview
    • 9.1.2 Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 In-house
    • 9.2.1 Overview
    • 9.2.2 In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Asia Pacific Biologics Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 China: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 China: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.2.2 China: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.2.3 China: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.2.4 China: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.3 India: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 India: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.3.2 India: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.3.3 India: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.3.4 India: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.4 Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 Japan: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.4.2 Japan: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.4.3 Japan: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.4.4 Japan: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.5 South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.5.1 South Korea: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.5.2 South Korea: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.5.3 South Korea: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.5.4 South Korea: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.6 Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.6.1 Australia: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.6.2 Australia: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.6.3 Australia: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.6.4 Australia: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.7 Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.7.1 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.7.2 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.7.3 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.7.4 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Manufacturing

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Market Initiative
  • 11.3 Partnerships and Collaborations
  • 11.4 Other Developments

12. Company Profiles

  • 12.1 AbbVie Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Samsung Biologics Co Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 ADMA Biologics, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 WuXi Biologics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Catalent Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AGC Biologics AS
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AstraZeneca Plc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Amgen Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Nitto Avecia
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Quality Assistance s.a.
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments

13. Appendix

  • 13.1 About Us